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Rabies is a viral zoonosis with 61,000 estimated deaths per year. Rabies vaccine is 
the best treatment pre and post exposure and virus can be produced in animal cells 
for veterinary use. This work had two objectives. The first one was to test three viral 
inocula (MOI 0.01, MOI 0.03 and 1% of working volume) in BHK-21 cells cultivated 
in 1.5 L spinner, comparing kinects and virus titration to determine the best 
inoculum. The second one was to freeze dry 12 formulations of excipients with an 
inactivated viral suspension, comparing visual aspects and residual moisture to 
select the best formulations. The best inoculum was 1% of working volume and the 
best excipients were trehalose, sucrose, dextran and mannitol. 
 



























Raiva é uma zoonose viral com 61.000 mortes estimadas por ano. A vacina 
antirrábica é o melhor tratamento pré e pós-exposição e o vírus pode ser produzido 
em células animais para uso veterinário. Este trabalho teve dois objetivos. O 
primeiro foi testar três inóculos virais (MOI 0,01, MOI 0,03 e 1% do volume de 
trabalho) em células BHK-21 cultivadas em spinner de 1,5 L, comparando 
resultados de cinética e titulação viral para determinar o melhor inóculo. O 
segundo foi liofilizar 12 formulações de excipientes com uma suspensão viral 
inativada, comparando aspectos visuais e umidade residual para selecionar as 
melhores formulações. O melhor inóculo foi 1% do volume de trabalho e os 
melhores excipientes foram trealose, sacarose, dextrana e manitol. 
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Presentation of the Institutions where the project was developed  
 
The present project was developed in two Institutions: Paraná’s Institute of 
Technology (TECPAR) and Parana’s Federal University (UFPR) both located in 
Curitiba, Paraná, Brazil. 
TECPAR is a public company founded in 1940 and linked to the Secretariat 
of Science, Technology and Higher Education of Paraná. TECPAR acts in two main 
areas: bioproducts and technology solutions. The bioproducts produced are anti-
rabies vaccine for veterinary use, tetan monomeric protein for production of triple 
vaccine (HIB – Haemophilus influenza type B for human use) and diagnostic test kit 
for detection of Leucosis, Tuberculosis and Brucellosis in cattle. The technology 
solutions include projects in energy, strategic studies and intelligent systems 
engineering for other companies.  
TECPAR produces the anti-rabies vaccine since 1944. The first method of 
production utilized bovine and equine brains as substrate. The method of 
production suffered several changes and nowadays the vaccine is made using cell 
culture as substrate. The Institute supplies the Ministry of Health with the anti-
rabies vaccine which is distributed for canines and felines in a national rabies 
vaccination campaign. TECPAR also does research and development to optimize 
the process and provide new forms of presentation of rabies vaccine, like the 
lyophilized form. 
UFPR was created in December 19, 1912 and is regarded as the oldest 
Brazilian University. According to Webometrics Ranking of World Universities, 
UFPR ranks 10
th
 in the Universities of Brazil and 15
th
 in the Universities across the 
Latin America. 
The University nowadays has facilities across the capital Curitiba and other 
cities of the State of Paraná. It offers 88 options of graduation courses, 52 master 
degrees and 35 doctoral programs. 
Between the graduation courses, the Bioprocess Engineering and 
Biotechnology is highlighted as one of the best courses, forming professionals 
capable of acting in several areas of knowledge such as industrial, environmental, 
health, agricultural, foods and beverages to list a few. The course was created in 
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1. Bibliographic Introduction 
 
 1.1 Rabies: disease, epidemiology and burden 
 
Rabies is a viral zoonosis that occurs in more than 100 countries and 
territories (Figure 1.1 in Annexes). There were 61,000 estimated cases of death 
from rabies in the world in the year 2010 according to the informal group Partners 
for Rabies Prevention (WHO, 2013). The estimated annual cost of rabies is US$ 6 
billion, covering pre and post exposure treatments and loss of productivity due to 
premature deaths of workers (WHO, 2013). 
 The infection usually occurs when an infected animal causes a transdermal 
bite or scratch in the victim. Transmission may also occur when infectious material, 
usually saliva, comes into direct contact with the victim’s mucosa or with fresh skin 
wounds. The incubation period is typically 1 to 3 months, but may vary from less 
than a week to more than a year (WHO, 2010). 
 Inoculated virus is transported to the central nervous system (CNS). On 
arrival in the brain, it replicates and disseminates rapidly in many different tissues 
including the salivary glands (WHO, 2010). The acute disease includes pain or 
paraesthesia close to the bite site and is often associated with fever, fatigue and 
weakness in associated limbs. Non-specific neurological symptoms including 
headache and anxiety are often experienced before the development of 
encephalitis and it is usually only at this point those patients seek medical help and 
admission to hospital (Johnson et al., 2010).  
As the virus spreads through the CNS, progressive fatal encephalomyelitis 
develops, characterized by hyperactivity and fluctuating consciousness and, in 
cases of furious rabies, hydrophobia or aerophobia, or both. Death occurs by 
cardiorespiratory arrest within a few days (WHO, 2010). 
 
 1.2 Rabies: classification, proteins and cell infection 
 
The rabies virus (RABV) belongs to order Mononegavirales and family 
Rhabdoviridae. This family has three genera: Vesiculovirus (which prototype is the 
vesicular stomatitis virus), Ephemerovirus (which prototype is the bovine ephemeral 
fever virus) and Lyssavirus (which prototype is the Rabies Virus) (Murphy et al., 
1995). RABV and variants known as “rabies related” virus belongs to one of the 
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fourteen Lyssavirus genotypes, all of them capable to produce a rabies-like 
encephalomyelitis (WHO, 2013). 
 The Lyssavirus stable infective particles (virions) have bullet-shaped form 
with average length of 180 nm and average diameter of 75 nm (Davies et al., 
1963). Lyssaviruses, like other Rhabdoviruses, consist mainly of RNA (2-3%), 
protein (67-74%), lipid (20-26%) and carbohydrate (3%) as integral components 
(percent of total mass) of their structure (Wunner, 1991). 
 The RABV genome is a non-segmented single-stranded RNA, which has a 
negative-sense polarity. This implies that the minus-strand genome RNA, when 
free of protein, is not infectious for the victim’s cells (Wunner, 2007). The genome 
analysis reveals the presence of five proteins: a nucleoprotein (N), a 
phosphoprotein (P), a matrix protein (M) a RNA polymerase RNA-dependent (L) a 
glycoprotein (G), which carries the main antigenic sites (Batista et al., 2007; WHO, 
2010). RABV structure is showed in Figure 1.2 in Annexes. 
 The cycle of infection and replication of RABV can be summarized in the 
following stages: (1) adsorption of virions to host cell, (2) penetration of the virion 
into the cell, (3) removal of protein-RNA complex proteins; (4) transcription of viral 
RNA, (5) translation of mRNAs, (6) processing of proteins, (7) viral RNA replication, 
(8) assembly of virions, and (9) budding (Nadin-Davis, 2010). A scheme of infection 
of a neuron cell is showed in Figure 1.3 in Annexes. 
 In the virion morphogenesis, the proteins N, P and L newly synthesized in 
the cytoplasm adhere to nascent viral RNA to form the nucleocapsid. The 
nucleocapsid is then stabilized by the M protein, which is responsible for giving the 
nucleocapsid its bullet-shaped morphology. The protein G, which requires 
glycosylation, is processed in rough endoplasmic reticulum and then goes to the 
host cell membrane. Finally, the nucleocapsid-protein M interact with cytoplasmic 
membrane fragments which contain protein G to finish virions assembling and 
proceeds to budding of these new virion to further spread of the virus (HIROSE & 
MONTAÑO-Villegas 1996; Wunner, 2007) 
 
1.3 Rabies vaccines: definition, generations and first rabies vaccine 
  
 A vaccine is any preparation intended to produce immunity to a disease by 
stimulating the production of antibodies (WHO, 2013). The most common method 
of administering vaccines is by injection. But some vaccines are given by mouth or 
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nasal spray (WHO, 2013). The first rabies vaccine was developed by Louis Pasteur 
and Emile Roux in 1885 (cited by Bunn, 1991).  
 Talking specifically about rabies, there were three generations of vaccine 
production: the first generation utilizes brains of rabbits, sheep, cows, horses and 
other animals as substrate for virus cultivation. In 1955, Fuenzalida and Palacios 
described a vaccine using suckling mouse brain as substrate (Fuenzalida & 
Palacios, 1955) and Peck and collaborators described a vaccine using duck 
embryonated eggs as substrate (Peck et al, 1955). The second generation uses 
cell cultures for producing rabies vaccine. In 1960, Fenje announced the first 
vaccine to be produced on hamster kidney tissue (Fenje, 1960). In the next years 
there were a great amount of reunions and congresses for debating of researches 
all over the world and standardization of the work which enabled the development 
and then the rapid commercialization of vaccines for veterinary use. This 
development benefitted from four favorable factors: (1) the cell lines, such as BHK 
(Baby Hamster Kidney), were accepted for the production of vaccines for use in 
animals; (2) viral multiplication is excellent in these cells; (3) these systems 
permitted an industrial scaling up of the cultures; (4) the addition of adjuvant was 
authorized to these veterinary vaccines (Roumiantzeff et al., 1985). The third 
generation of rabies vaccines is already available: the vaccinia-rabies glycoprotein 
recombinant vaccine is presently applied on a large scale in some European 
countries for immunization of wildlife. The canarypox recombinant vaccine has 
already been considered and successfully tested for human immunization (Sureau, 
1992). 
Talking about vaccine production itself, after cell growing and virus 
production it is necessary to inactivate the virus. Beta-propiolactone (BPL), 
ultraviolet (UV) light and acetylethyleneimine are used as inactivating agents, and 
BPL is the most utilized (Reculard, 1996). Once inactivated, adjuvants are added to 
increase the immune response to the antigen. The most used are aluminum 
hydroxide, aluminum phosphate, saponin and less commonly used are oil 
adjuvants (Precausta et al., 1991, Briggs et al., 2002).    
 
1.4 Rabies vaccines: TECPAR production 
 
TECPAR used Fuenzalida-Palacios method to produce rabies vaccine for 
veterinary use over forty years before change it for cell culture vaccine. Since 2010, 
the Brazilian regulatory agency (MAPA) that control the production of rabies 
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vaccine established mandatory the utilization of a different substrate other than 
mouse brain. To fit the new specifications, TECPAR started to use BHK-21 cells 
growing in suspension on a stirred bioreactor to produce rabies vaccine.  In 
addition, the bioreactors were equipped with a perfusion system (Aurelio Zeferino, 
personal communication, 2012). 
 Animal cells grow substantially slower than most microorganisms, and 
lacking a protective cell wall, they are also more fragile. Therefore, one is limited to 
very gentle culture conditions and relatively low cell concentrations. One way to 
increase the cell concentration, yet maintain gentle culture conditions is the 
perfusion method (Furey, 2000).  
A perfusion culture is one in which waste medium is continuously removed 
from the culture and the displaced medium is replenished with fresh medium. The 
constant addition of fresh medium and elimination of waste products provides the 
cells with the environment they require to achieve high cell concentrations and with 
that higher productivity (Furey, 2000). 
In the context of virus multiplication in cells, the concept of Multiplicity of 
infection (MOI) must be explained. MOI is a frequently used term in virology which 
refers to the number of virions that are added per cell during infection. If one million 
virions are added to one million cells, the MOI is one. If ten million virions are 
added, the MOI is ten. Add 100,000 virions, and the MOI is 0.1 (Racaniello, 2011).  
High MOI is used when the experiment requires that every cell in the culture 
is infected. By contrast, low MOI is used when multiple cycles of infection are 
required. However, it is necessary to determinate the virus titer in order to calculate 
the MOI (Racaniello, 2011). 
Perrin and collaborators (1995) tried to develop a rabies vaccine using BHK-
21 cell suspension culture in bioreactor with perfusion in 1995 with satisfactory 
results. They utilized different MOI for each stage of the adaptation of the cells from 
monolayer to suspension: 0.003; 0.01; 0.1 and 0.3 cells
-1
.  
Kallel and collaborators (2002) tested various serum and protein free media 
for production of rabies vaccines. In spinners, the MOI selected was 0.1 cells
-1
. In 
bioreactors the MOI was 0.1 or 0.3. Works with the same MOIs were conducted in 
Vero cells by Trabelsi and collaborators (2005, 2006). Guidolin and collaborators 
(1983) also tested two different MOI (0.07 and 0.046 cells
-1
) for producing rabies 
vaccines in BHK cells, obtaining satisfactory potency results.  
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1.5 Lyophilization: process, use for immunobiologicals and cryoprotectors 
most used for vaccines 
 
 Lyophilization, or freeze drying, is defined as a stabilizing process in which 
the substance is first frozen and the quantity of the solvent is reduced by 
sublimation (primary drying). After, a secondary drying (desorption) the reduction 
achieve values that will no longer support biological growth or chemical reactions. 
The lyophilization process is composed by five phases: (1) formulation, (2) freezing, 
(3) primary drying, submitted to vacuum, (4) secondary drying and (5) closure of 
recipients (Jennings, 2008). 
 Freeze drying is an established process to improve the stability of labile 
drugs, especially proteins and complex vehicles like virus vaccines, viral vectors, 
liposomes and lipid–DNA complexes. However, during freezing and subsequent 
drying, the drug is exposed to diverse stress factors which can cause significant 
loss of activity. During freezing, drug stability can be influenced by exposure to ice–
water interfaces, salt and drug concentration effects, pH shifts due to selective 
crystallization of buffer species, and mechanical damage by growing ice crystals. 
During drying, removal of stabilizing hydration shells can influence the stability of 
the drug, just to mention the most common known degradation causes (Wang 
2000; Lang & Winter, 2009). 
Then, to ensure the drug stability in step drying freeze and subsequent 
storage, stabilizing excipients have to be employed. Cryoprotectants such as salts, 
polyols, and sugars are used to stabilize the solution therapeutic in freeze thawing 
process. Lyoprotectants, especially the disaccharides sucrose and trehalose, can 
be used to stabilize the drug during drying. Additionally, bulking agents as like 
mannitol can be added to enable faster drying times and to maintain lyophilisates 
with an attractive appearance (Wang 2000; Lang & Winter, 2009).  Hubálek in 
2003 described a list of different cryoprotectors used in microorganism’s 
conservation. These include: sulfoxides; alcohols and derivatives; saccharides and 
polysaccharides; amides and imides; heterocyclic compounds; amino acids, 
proteins, peptides and polypeptides; complex compounds; and surfactants.  
 It’s not necessary to freeze dry the rabies vaccine for veterinary use 
according to Brazilian regulatory agency (MAPA). Although, the lyophilization does 
not exclude the cold chain (2 to 8°C), the vaccine in the lyophilized form is more 





This work has two main objectives: 1- study different multiplicities of 
infection in order to determine the best inoculum for infection of cell cultures in 
spinner; 2- select the best excipients in order to freeze dry the rabies vaccine for 
posterior in vivo tests.    
 To achieve that, the specific objectives are: 
1) Determine the cellular growing kinects before and after virus infection; 
2) Determine the viral production with different virus inoculum conditions;  
3) Determine the influence of these inoculum seeking greater productivity 
and higher quantity of harvests above cut off (established by TECPAR);  
4) Evaluate the visual aspects and residual moisture of different 
lyophilization conditions; 























3. Material and Methods 
 
3.1 Culture Medium 
 
The medium used for growing BHK-21 cells before infection was nominated 
SCM (Standard Culture Medium). It was composed by a combination of DMEM 
(Dulbecco’s Modified Eagle Medium) and Ham’s F12 Nutrient Mixture Medium 
customized for TECPAR use, supplemented with 3% of fetal bovine serum (FBS) 
and with pH adjusted for 7.8.  
After the cell infection with virus particles the medium used was nominated 
SCMI (Standard Culture Medium for Infection). It was composed by DMEM and 
Ham’s F12 medium but supplemented with 1% of FBS and with pH adjusted for 
7.8. 
The BHK cells of seed bank and work bank were frozen in liquid nitrogen 
using a medium nominated FM (Freezing Medium). It was composed by 95% FBS 
and 5% dimethyl sulfoxide (DMSO). 
 
3.2 Cell line and virus strain 
 
The cell line used was BHK-21 C13 LVI and it came from Pan American 
Centre for Foot-and-Mouth Disease (Panaftosa) with 84 passages. The cells were 
adapted in SCM and a seed bank was made using 30 million cells/mL in FM 
aliquoted in cryotubes and stored at -196°C in liquid nitrogen with 105 passages.  
From the seed bank it was prepared a work bank which was used for the 
experiments of cultivation of cells in spinner flask. At the experiments, the cell line 
had 118 passages.  
The rabies virus strain was Pasteur Virus (PV) adapted for the infection of 
BHK-21 C13 cells and has one passage. The strain came from Minas Gerais’ 
Federal University (UFMG) and was storage at -80°C ultra freezer. From the 
original virus was created a seed bank and a work bank, both prepared in BHK 
cells cultivated with SCM and supplemented with 5% (w/v) sucrose before freezing. 







3.3 Cell counting 
 
The cells were counted in hemocytometer. The readings were performed in 
optical microscope Olympus with 100 times magnification. The cells were stained 
with 0.5% (w/v) Trypan blue in a dilution in which at least 20 cells could be counted 
per quadrant (Phillips, 1973). The cells were also visually evaluated in terms of 
morphology, light refringence and size.     
 
3.4 BHK-21 cell production for infection in spinner for development 
experiments 
 
 A cryotube with BHK-21 cells from the work bank was thawed at 37°C and 
used as cell inoculum in a 500 mL spinner (named 1A) with 80 mL of SCM. The 
spinner was incubated at 37°C at 55 rpm agitation and cell counting was made 
every day. When it achieved at least 800,000 cells/mL, more medium was added to 
dilute the cells to 200,000 cells/mL and the spinner was incubated again. This 
proceeded until the spinner has 500 mL of SCM.  
After that 250 mL of first spinner was transferred to a 1.5 L spinner. SCM 
was added to this second spinner to complete 1.25 L leaving it with 200,000 
cells/mL again and this second spinner was incubated at 37°C at 55 rpm. When the 
concentration reached 1 million cells/mL, the sample was divided in four spinners 
(1.1A, 1.2A, 1.3A and 1.4A) each one was completed to 1.5 L with SCM. The four 
spinners were incubated with the same conditions. When the concentration of the 
four spinners reached at least 1million cells/mL each, three of the spinners were 
infected with the virus strain.  
 
3.5 Cell culture infection in spinner for development experiments 
 
 The virus titer for the experiment was 10
6.18
 Fluorescent Focus-Forming 
Dose (FFD) per mL, titrated in microplate. The MOI calculations were made using 





Figure 3.1: Formula for calculating the correct volume for infection of spinners. 







- Volinoculum = volume of inoculum required for the infection, in mL; 
- MOI = multiplicity of infection selected, in FFD/cell; 
- Celtot = total number of cells, multiplying the cell concentration for the 
volume of the flask, in cell; 
- Antilog Tit = the anti-logarithm of virus titer, in FFD/mL;  
 
In the development stage assay there were selected three different MOI for 
infection. The virus used for all the infected spinners was at the same 
concentration, therefore the only difference was the volume inoculated in each 
spinner. The inoculum used corresponding to 1% of total flask volume (as example 
15 mL in 1.5 L spinner) is the positive control, used normally for rabies vaccine 
production on bioreactor. Using the formula it can be calculated that positive control 
has MOI 0.015 FFD/cell. The experiments also used MOI 0.01 and 0.03 FFD/cell.  
 When 1 million cells/mL was reached in the spinners, the infection protocol 
was started. In zero day of infection, the pH was adjusted for 7.4 with sodium 
bicarbonate 7.5% (w/v) and the spinner was placed in a cold room (2 to 8°C) for 2 
hours to sediment the cells. The supernatant was carefully removed from the 
spinner, leaving a final volume of 300 mL. Then diethylaminoethanol-dextran 
(DEAE) 0.5% (w/v) was added at 1% of the remaining volume to optimize the 
adsorption of the viral particles in the cells. The spinner was incubated at 33°C in 
intermittent agitation: 20 minutes stopped and 5 minutes with 30-35 rpm agitation 
for 90 minutes.  
The four spinners were nominated: Spinner 1.1A became positive control 
and received 15 mL of virus; Spinner 1.2A became negative control and it wasn’t 
inoculated with virus; Spinner 1.3A became MOI 0.01 and received 10 mL of virus; 
Spinner 1.4A became MOI 0.03 and received 30 mL of virus. 
After inoculation the volume was completed to 1.5 L with SCMI and 
incubated at 33°C at 55 rpm. The assay lasted 10 days after infection. The next 
days were called days post infection (dpi). In each day, samples were taken for cell 
counting, infection rate, pH evaluation, glucose and lactate determination and two 
samples were frozen for subsequent virus titration. The pH was adjusted to 7.4 with 
sodium bicarbonate 7.5% and the spinner was placed in cold room for cell 
sedimentation for 2 hours. The maximum volume of medium was discarded, 
without losing cells, and new SCMI was added in order to achieve 1.5 L again and 
the spinner was incubated in 33°C at 55 rpm. From 3 dpi to 8 dpi, the medium was 
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harvest instead of discarded, placed in 2 L roller bottles, identified and stored at -
80°C.  
  After counting the viable and total cells it was possible to calculate the 
viability in percentage. Also, the specific growth rate (µ) can be calculated with an 
formula adapted for using cell concentration values obtained at the assay (Figure 
3.2). The specific growth rate measures the rate of cell multiplication and it is 





Figure 3.2: Formula for calculating specific growth rate of cell cultures. 
 
 Where: 
- µ = specific growth rate, in hours
-1
; 
- X = cell concentration, in cells/mL; 
- t = time, in hours; 
- n and n-1 means two succeeded sampling points.  
 
3.6 Glucose and lactate determination 
 
Every day a sample of each spinner was taken in microtube and centrifuged 
at 800 rpm for 5 minutes. Then the supernatant was injected in an YSI 2700 Select 
Dual-Channel Biochemistry Analyzer (Yellow Springs Instruments, Yellow Springs, 
Ohio, USA) for determination of residual glucose and lactate production 
concentration.  
 
3.7 Infection rate by direct immunofluorescence  
 
The direct immunofluorescence test was adapted from Batista and 
collaborators, 2009. 
The test was carried out with 50 µL of the three infected cultures in 
separated spaces of a lamina. The lamina was placed on a flat table for 20 min to 
sediment the cells and dried at room temperature. The next step was fixating the 
cells using 50 µL of acetone 80% (v/v) in purified water. The lamina was conserved 
𝜇 =





in freezer (-20°C) for 7 minutes. Then, the acetone was thawed and the lamina was 
dried at room temperature. 
Afterwards it was prepared a solution with anti-rabies nucleocapsid 
conjugate (Bio-rad code 357-2114) and Evans blue dye (dissolved at 1:40000 in 
purified water) at 1:20 proportion and 40 µL was added to three samples. The 
lamina was incubated at 37°C for 30 min and then washed three times with 50 µL 
of PBS.  
Finally a glass slide was put over the lamina (Figure 3.3) and it was 
observed in an immunofluorescence microscope Olympus with 100 times 
magnificence. 
 The samples were evaluated in terms of fluorescent focus inside the cells. 
The results were classified like described in Table 3.1 
 
Table 3.1: Classes and requirements for evaluate direct immunofluorescence. 
 
 
3.8 Rabies virus titration 
 
The rabies virus titration of samples was made following the Fuches, 2010, 
protocol previously validated by Moura and colleagues, 2008.   
From each infected spinner (in each dpi) a sample was taken totalizing 10 
samples per spinner, and centrifuged at 800 rpm for 5 minutes. The supernatant 
was collected and stored at -80°C. These samples were thawed at room 
temperature at the time of experiment. A reference rabies virus with known titration 
was used, in duplicate and 2 wells were used for cell control, without infection. 
Three microplates with 96 wells were made, each one with the 10 samples 
(one for each dpi) of one infection. The disposal of the samples and the dilutions 
used in the titration are described in Annexes (Table 3.2 and Figure 3.4). 
 
Class Requirements 
0 total absence of fluorescent focuses 
1 from rare fluorescent focuses to 25% fluorescent focuses 
2 from 25% to 50% fluorescent focuses 
3 from 50% to 75% fluorescent focuses 
4 more than 75% fluorescent focuses 
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3.9 Preparation of a vaccine for the lyophilization experiments 
 
For the lyophilization experiments, an inactivated viral suspension (IVS) 10 
times concentrated previously prepared in 75 L NBS bioreactor was used. This IVS 
was selected in order to test different lyophilization protocols before using the 
harvests obtained in the development stage and evaluate the performance of the 
excipients selected.  
The harvests from the bioreactor usually have a few cellular debris and 
another undesirable metabolites. When the IVS is concentrated, these debris are 
concentrated too. Then it was necessary to clarify this IVS, washing it with buffer 
solution. The buffer selected was NT (Table 3.3 in Annexes). Before the buffer 
exchange, it was necessary to concentrate the IVS in order to improve the wash 
results and to use a minor amount of buffer solution. 
The buffer exchange step was performed in a Pellicon tangential filtration 
system with 100 kDa of porosity (Merck-Millipore, Billerica, Massachusetts, USA). 
The Pellicon membrane was coupled with a peristaltic pump set up for 55rpm 
speed. Firstly, the IVS were concentrated from 2 liters to 400 mL, discarding the 
permeate. Secondly, buffer were continued added to the IVS to wash, totalizing a 5 
times volume, also discarding the permeate. Finally, the volume was reestablished 
with the same buffer and thimerosal 10% was added at 1:10,000 proportion to 
preserve the IVS. The IVS were stored at cold room.  
 
3.10 Selection of excipients for lyophilization  
 
For the lyophilization experiments, 11 excipients were selected: 
- 3 disaccharides: sucrose, trehalose and lactose;  
- 2 polyalcohols: sorbitol and mannitol;  
- 3 amino acids: L-proline, L-serine and L-glutamic acid,  
- 3 polymers: dextran 40 (a polysaccharide with molecular weight 40 kDa), 
polyethylene glycol (PEG) 3350 (a polyether with average molecular weight 3350 
Da) and gelatin.  
A summary of the selected excipients, theirs respective classes and their 
estimated prices in dollars is described in Table 3.4. The most expensive excipient 
is the polymer dextran 40 (4,522 dollars per kilogram) and the cheapest excipient is 




Table 3.4: Type and cost of the selected excipients. 
 
 
The excipients were diluted in purified water (Milli-Q) for the lyophilization 
experiments and prepared 2 times concentrated in order to prepare stock solutions 
of each excipient which were used during all the experiments (Table 3.5)  
 
















Excipients Type Estimated Cost 
Sucrose Sugar US$ 86/kg 
Trehalose Sugar US$ 4,211/kg 
Lactose Sugar US$ 193/kg 
Sorbitol Polyalcohol US$ 55/kg 
Mannitol Polyalcohol US$ 232/kg 
Proline Amino acid US$ 1,263kg 
Serine Amino acid US$ 1,280/kg 
Glutamic Acid Amino acid US$ 162/kg 
Dextran 40 Polymer US$ 4,522/kg 
PEG 3350 Polymer US$ 254/kg 
Gelatin Polymer US$ 142/kg 








Glutamic Acid 2% 
Dextran 40 2% 




3.11 Preparation of excipient solutions and vaccine formulation  
 
Each vaccine is IVS with a different excipient solution. The vaccine 
formulation was done mixing together the IVS and the excipients at 1:1 proportion, 
homogenizing it and making 1 mL aliquots in 7.5 mL glass vials. The vials were 
partially closed with a rubber stopper (Figure 3.5 in Annexes) in order to permit 
water vapor from sublimation to escape. At the final, the vaccine had the IVS five 
times concentrated and the excipient solutions at half the stock solution 
concentration.  
Five vials were prepared for each excipient solution. An additional of five 
vials with 1 mL were prepared with only the IVS diluted in purified water to achieve 
five times concentration. This unprotected formulation was used for comparison of 
results.  
 
3.12 Lyophilization process 
 
The lyophilization experiments were developed in a freeze dryer Edwards 
RC-300 (Edwards Vacuum, Crawley, West Sussex, UK). After preparation of the 
partially closed glass vials with vaccine formulations, the vials were disposed in the 
trays of the equipment. The trays were placed inside the freeze dryer and the 
protocol was started. 
The protocol had 3 steps: freezing, primary drying and secondary drying. 
Several protocols were tested with the vaccine formulations in the freeze dryer, 
finally establishing the best lyophilization protocol. This protocol (Table 3.6) was 
used to freeze dry the different vaccine formulations.  
 
Table 3.6: Description of the best lyophilization protocol. 
Step Temperature Duration 
Freezing -42°C 3 hours 










3.13 Visual aspects evaluation of lyophilized vials 
 
The lyophilized vials were visually evaluated using three parameters: color, 
integrity and uniformity. The color of the IVS without any excipient was white, so the 
excipient must not make modifications in the cake color to pass the color test. The 
cakes must have uniform mass distribution to pass the uniformity test. The cakes 
must not present cracks to pass the integrity test. 
The cakes were reconstituted with purified water. Two other parameters 
were evaluated under this condition: time of reconstitution and pH. The time of total 
reconstitution of cakes must not exceed one minute. The pH of the reconstituted 
cakes was also measured and must be between 6.8 and 8.5 (Brasil, 1988).  
 
3.14 Residual moisture test 
 
The residual moisture test was done by volumetric Karl Fischer titration in 
Titroline KF equipment (Schott SI Analytics, Mainz, Rhineland-Palatinate, 
Germany). The best three lyophilized vials of each formulation were selected for 
the test. The samples of each vial were weighted and titrated in the Karl Fischer 
equipment. The residual moistures as well as the mean values were calculated. 
The residual moisture must not pass 3% for the lyophilized rabies vaccine (Brazil, 
1988). 
4. Results and Discussion 
 
4.1 Kinects results and comparisons 
 
 The main objective of the development experiments was to evaluate the 
best viral production. However it was important to obtain growth curves of the four 
spinners in order to analyze and compare the infected cultures with the negative 
control in terms of kinects, specific growth rate and metabolites consumption and 
production. This development experiment was able to tell the influence of the 
different MOI in the spinners and compare the results with a not infected spinner. 
 
4.1.1 BHK-21 cell production 
 
After 10 days of experiment, the growth curves for the fours spinners were 





Figure 4.1: Cell growth curves obtained for the four spinners cultivation in 
development experiments. After 10 days of infection, the negative control of assay 
achieved maximum cell concentration of 1.78 million cells/mL (viable cells) at 6 dpi 
(days post infection). The positive control achieved maximum cell concentration of 
1.33 million cells/mL (viable cells) at 6 dpi. The spinner MOI 0.01 reached a 
maximum of 1.33 million cells/mL (viable cells) at 5 dpi. The spinner MOI 0.03 
achieved its maximum  with 1.22 million cells/mL (viable cells) at 4 dpi. 
 
In terms of cell production, the negative control of assay achieved maximum 
cell concentration of 1.81 million cells/mL (total cells) and 1.78 million cells/mL 
(viable cells) at 6 dpi. After 6 dpi, the growth rate began to decrease, reaching 1.08 
million viable cells/mL at the end of the assay. The cell concentration obtained in 
negative control was similar to normal cell production at TECPAR (data not 
showed). 
The positive control of the assay was infected with 15 mL of virus. Maximum 
cell concentration was 1.43 million cells/mL (total cells) and 1.33 million cells/mL 
(viable cells) at 6 dpi. After 6 dpi, the growth rate began to rapidly decrease, 
reaching 355,000 viable cells/mL at the end of the assay. The growth curve had a 
slightly decrease between 3 and 4 dpi, probably because of intense virus 
production, restarting the growth between 4 and 5 dpi.  
The spinner with MOI 0.01 was infected with 10 mL of virus. Cell 
concentration reached a maximum of 1.48 million cells/mL (total cells) and 1.33 













































after this began to decrease reaching 600,000 viable cells/mL at the end of the 
assay.  
The spinner with MOI 0.03 was infected with 30 mL of virus. Cell 
concentration achieved its maximum with 1.29 million cells/mL (total cells) and 1.22 
million cells/mL (viable cells) at 4 dpi. After 4 dpi, the growth rate rapidly decreased 
at 5 dpi, stabilized at 6 and 7 dpi and then decreased again, reaching 450,000 
viable cells/mL at the end of the assay.  
The peak of growing for the different infected cultures was different: 6 dpi for 
positive control, 5 dpi for MOI 0.01 and 4 dpi for MOI 0.03. The peak of MOI 0.03 
was achieved faster probably due the virus concentration that was the highest and 
started to make effect on the culture earlier than the others. Nevertheless, the 
infected cultures achieved similar peaks of concentration and the oscillations of 
growing were practically constant. 
Perrin and collaborators (1995) used two different 2 L bioreactors (1.3 L 
working volume) to produce rabies vaccine using BHK-21 cells in perfusion mode. 
The maximum cell density in the two bioreactors was close to 6 million cells/mL. 
Kallel and collaborators (2002) also developed an experiment for producing rabies 
vaccines in BHK-21 cells in 250 mL spinner and 2 L (1.3 L working volume) 
bioreactor. The maximum cell concentration obtained was 2 million cells/mL in non-
infected spinners and 1.2 to 1.6 million cells/mL in infected spinners. In bioreactors, 
the maximum cell density achieved 3 million cells/mL in batch mode.  
The results for the four spinners were similar to those obtained by Kallel and 
collaborators (2002) although the four spinners used a higher amount of medium 
volume. Also cultures with the same volume in bioreactor had better cell production 
than spinner. This happened because the bioreactors possess better controls for 
temperature, dissolved oxygen, pH and agitation. So then, using bioreactors with 
the same volume of the experiment (1.5 L) would increase cell production. 
Additionally, using a perfusion system coupled with bioreactor would imply in even 
better results.  
Using the formula described in Figure 3.2, the specific growth rate (µ) could 






Table 4.1: Maximum specific growth rate for the four spinners. 
Spinner µ max (h
-1
) dpi of µmax  
Neg. Control 0.010 1 dpi 
Pos. Control 0.013 2 dpi 
MOI 0.01 0.014 5 dpi 
MOI 0.03 0.020 1 dpi 
 
A characteristic of animal cells like BHK-21 is that, even under optimized 
conditions of growing, present a low specific growth rate, between 0.01 h
-1
 and 0.05 
h
-1
. That µ is significantly lower than specific growth rates presented by 
microorganisms thus making the industrial process costlier (Tonso, 2000). 
The four spinners achieved a µmax compatible with the optimized cultures 
although the spinners had poor process controlling which means that the cultures 
grown satisfactorily. 
 
4.1.2 Viability of cell cultures 
 
The viability was obtained in percentage, dividing viable cells by total cells 
and multiplying 100 times. From the results, the highest, the lowest and the mean  
value for viability were obtained (Table 4.2). 
  
Table 4.2: Rate of cell culture viabilities for the four spinners. Between brackets is 
the days post infection (dpi) where the viability was achieved 
Spinner Highest viability  Lowest viability Mean viability 
Neg. Control 98.3% (6dpi) 88.2% (0dpi) 95.4% 
Pos. Control 96.2% (3dpi) 66% (8dpi) 87.7% 
MOI 0.01 95.4% (7dpi) 85.6% (8dpi) 91.1% 
MOI 0.03 97.5% (3dpi) 75.7% (8dpi) 90.8% 
 
The viability of negative control was the highest because of the absence of 
virus. Therefore cell concentration was limited by other factors like absence of gas, 
pH and temperature control, agitation and accumulation of some metabolites and 
debris that could interfere in cell growing.  
The virus does not kill the cell because the new virions are released outside 
by budding. Not infected cells replicate normally although, one infected cell does 
not replicate anymore, only producing more virus until its death. So then, with a 
lower quantity of virus as inoculum, the tendency is to achieve a better viability 
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because the cells will take a longer time to become infected and die. The spinner 
with MOI 0.01 has the best viability among infected spinners because of the lower 
quantity of virus inoculated. 
Chapman and collaborators (1973) studied the viability of BHK-21 cells 
infected with rabies virus and kept in two temperatures, 33°C and 36°C. MOI 0.05 
was used in this experiment, corresponding to 1% of the final volume of the vessel, 
just like the positive control. The viability of cells after infection at 36°C decreased 
from 3 dpi reaching almost 0%. However, the viability of infected cells at 33°C 
remained above 90%, just as founded in the development experiment. 
 
4.1.3 Metabolites consumption and production 
 
Daily samples were taken and evaluated in terms of glucose consumption 
and lactate production for the four spinners (Table 4.3).  
 
Table 4.3 Minimum glucose concentration and maximum lactate production for the 
culture cells in four spinners during the 10 days of infection. Between brackets is 







Animal cells need glucose and glutamine as carbon sources. In the glucose 
metabolism practically all of glucose is converted in lactose. Thus, the relation 
between glucose consumption and lactate production represent important 
parameters for process monitoring and providing information about the metabolic 
flow inside the cells (Zeng et al., 1998; Tonso, 2000).   
Cruz and collaborators (2000) studied the effects of lactate inhibition on 
BHK cells. When lactate concentration achieved 28 mM (which correspond to 2.52 
g/L), cell growth was reduced. Therefore in none of the spinners, the lactate 




Spinner Min. Glucose Conc.  Max. Lactate Conc.  
Neg. Control 1.20 g/L (8dpi) 2.33 g/L (8dpi) 
Pos. Control 2.63 g/L (6dpi) 1.42 g/L (7dpi) 
MOI 0.01 2.04 g/L (5dpi) 1.81 g/L (5dpi) 
MOI 0.03 2.78 g/L (8dpi) 1.14 g/L (5dpi) 
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Usually the cultures in 1.5 L spinner are made with 1.25 L working volume. 
The volume used in the developed experiments was 1.5 L. This was an attempt of 
increase the cell production, providing more carbon source to cells. Unfortunately 
the cell production in the experiment was close to cell concentrations usually 
obtained in 1.25 L. Furthermore, the glucose remained with high concentration in 
positive control and MOI 0.03 spinners, which means that the medium change 
during days post infection threw away medium that was still good for cell growing, 
generating a waste of money.  
 
4.2 Infection rate results 
 
 The infection rate is a qualitative method to evaluate the behavior of virus 
inside the cells during the cultivation. Table 4.4 summarizes the results for infection 
rate found in the three infected spinners. Figure 4.2 in Annexes shows examples of 
classification of infection rate. 
 
Table 4.4: Infection rates of virus inside cells. 
 
 
However, the infection rate does not reflect on the production of virus inside 
the cells and the quality of virus produced. The direct immunofluorescence is one 
tool for process control and only classifies the infection rate inside the cells. This 
technique can be used to predict on which dpi the harvests can be initiated. 
Normally when the culture reaches Class 4 it means that harvests can be made. 
This happened for all spinners at 3 dpi, and that was the day that harvests were 
initiated. 
Dpi Pos. Control MOI 0.01 MOI 0.03 
1 Class 1 Class 1 Class 1 
2 Class 3 Class 2 Class 4 
3 Class 4 Class 4 Class 4 
4 Class 4 Class 4 Class 4 
5 Class 4 Class 4 Class 4 
6 Class 4 Class 4 Class 4 
7 Class 4 Class 4 Class 3 
8 Class 3 Class 4 Class 3 
9 Class 3 Class 4 Class 3 
10 Class 3 Class 4 Class 4 
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 From the results it can be concluded that the inoculum with the lowest 
concentration of virus took a longer time to achieve Class 4 (more than 75% of 
fluorescent focuses). Also, oscillations between Class 3 and Class 4 are normal 
depending if cells are replicating, which would imply in less fluorescent focuses, or 
producing virus, which would imply in more fluorescent focuses. 
 
4.3 Virus titration results 
 
 The virus titration is an important tool to evaluate viral production and quality 
in several stages of vaccine production (Fuches, 2010). It is a relatively fast in vitro 
test (when compared to in vivo tests) to evaluate the infection of virus produced in 
other cells and compare the results with a standard virus. Butantan Institute in 
Brazil made a comparative study which showed a good correlation between the 
virus titration results and the potency results performed in mice but the data was 
not published (Fuches, 2010). 
 The virus samples from the three infected spinners collected during the ten 
days of infection were titrated (Figure 4.3). Also, in Annexes shows examples of 
field classification in virus titer determination (Figure 4.4). 
 
Figure 4.3: Virus titration curves for the three infected spinners Only harvests 
above cut off are used for rabies vaccine production. The maximum titration value 
reached by positive control was 105.98 FFD/mL at 4 dpi. The maximum for MOI 
0.01 was 105.37 FFD/mL at 3 dpi and for MOI 0.03 was 105.77 FFD/mL at 4 dpi. 
The best graphic area above cut off means the best inoculum. In this case, the best 





































The titration for the standard virus was 10
5.37
 FFD/mL. The maximum 
titration value reached by positive control was 10
5.98
 FFD/mL at 4 dpi. The 
maximum for MOI 0.01 was 10
5.37
 FFD/mL at 3 dpi and for MOI 0.03 was 10
5.77
 
FFD/mL at 4 dpi. Harvests of virus from infected spinners were made from 3 dpi to 
8 dpi and kept in ultrafreezer at -80°C.  
TECPAR uses harvests from the bioreactor to produce rabies vaccine. 
These harvests are also titrated in order to evaluate the virus production and 
determine the best results. After several attempts to produce a vaccine with great 
potency using different titers, it was established a cut off at 10
3.8
 FFD/mL and 
harvests with virus titer lower than cut off should not be used to produce rabies 
vaccine (no published data).  
Same reasoning was applied in the spinner cultures. The best viral inoculum 
determination took into account how many harvests were above the cut off and 
among these harvests which present the best results or in a better way, which 
inoculum obtained the larger graphic area above cut off. 
Among the days where harvests occurred, all of the infected spinners had 
six harvests above the cut off. However, positive control and MOI 0.03 obtained two 
more harvests above the cut off that were not collected. Between the harvests 
above cut off, it can be seen that the positive control have the largest graphic area 
above cut off.  
Based on all information showed and calculated it can be concluded that 
positive control is the best inoculum for spinner infection. This viral inoculum is 
made by adding a viral volume correspondent to 1% of the volume of the vessel 
utilized in the experiment is the best way to infected one BHK-21 culture with rabies 
virus. 
  
4.4 Lyophilization results 
 
4.4.1 Visual aspects evaluation 
 
 After the IVS was formulated with different excipients and aliquoted in the 
glass vials, the lyophilization protocol was started and the resultant lyophilized 



















Figure 4.5: Lyophilized cakes part one.  
A= IVS without excipient; B= Lactose 5%; C= Mannitol 5%; D= Sucrose 5%; E= 
Sorbitol 5%; F= Trehalose 5%. All the sugars presented good cakes as well as 
mannitol, the IVS without excipient formed a heterogeneous cake and the sorbitol 














Figure 4.6: Lyophilized cakes part two. 
G= Glutamic acid 1%; H= Serine 1%; I= Proline 1%; J= Dextran 40 1%; K= Gelatin 
1% and L= PEG 3350 1%. All the amino acids formed collapsed cakes, as well as 
PEG3350, dextran 40 formed an excellent cake and gelatin presented a 
heterogeneous cake. 
 
 The lyophilized cakes were visually evaluated in terms of the lyophilized 
cakes in terms of color, uniformity, integrity (Table 4.5).  
A B C D E F 
L K J I H G 
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Table 4.5: Visual aspects evaluation of lyophilized cakes. The “X” symbolizes cakes 
that pass the tests. 
Excipient Color Uniformity Integrity 
Pure IVS X  X 
Sucrose X X X 
Trehalose X X X 
Lactose X X X 
Sorbitol X   
Mannitol X X X 
Proline X   
Serine X   
Glutamic Acid X   
Dextran 40 X X X 
PEG 3350 X   
Gelatin X  X 
 
 The lyophilization of amino acids as excipients did not produce good cakes. 
The samples presented collapsed during lyophilization (process also known as melt 
back). The same phenomenon happened with sorbitol. PEG 3350 cakes melt back 
too but appeared drier than sorbitol and amino acids cakes. IVS and gelatin did not 
pass the uniformity test because of the bubbles presented.  
 All excipients did not aggregated color to the cake and passed the color test. 
The best excipients in this step were: sucrose, lactose, trehalose and dextran.  
After reconstituting the vaccine with purified water, two parameters were 
evaluated: time of reconstitution and pH of the reconstituted cakes (Table 4.6).  
Table 4.6: Time and pH evaluation of reconstituted cakes. The “X” symbolizes 
formulations that achieved the specified time of reconstitution.  
  
Excipient Time of reconstitution Final pH 
Pure IVS X 7.58 
Sucrose X 7.52 
Trehalose X 7.56 
Lactose X 7.54 
Sorbitol X 7.55 
Mannitol X 7.58 
Proline X 7.56 
Serine X 7.32 
Glutamic Acid X 3.47 
Dextran 40 X 7.56 
PEG 3350 X 7.57 
Gelatin  7.4 
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 The only excipient that did not pass the time of reconstitution test was 
gelatin which did not solubilize in purified water in less than a minute. Although the 
other excipients had passed, the time of reconstitution was better in pure IVS, 
sucrose, mannitol and dextran. Lactose and trehalose took a while longer to 
become homogenized. The excipients with worse cakes, like all amino acids and 
PEG, took more time for reconstitution but achieved total homogenization in less 
than one minute. 
The Brazilian regulatory agency (MAPA) demands that the reconstituted 
vaccine have pH between 6.8 and 8.5 (Brasil, 1988). The only excipient that did not 
pass the pH test was glutamic acid which turned the vaccine more acid than 
recommended.  
  
4.4.2 Residual moisture evaluation 
 
Three samples were measured by Karl Fischer volumetric titration in terms 
of residual moisture and the mean moisture was calculated (Table 4.7).  
 
Table 4.7: Residual moisture results for lyophilized cakes. 
  *NC: not calculated 
 
The Karl Fischer titration is done injecting a known mass in the equipment 
and analyzing the quantity of Karl Fischer reagent necessary to react with residual 
water in the sample. Cakes obtained for the amino acids and PEG 3350 could not 
be removed from lyophilized vials for injection in the titration equipment because 
Excipient RM1 RM2 RM3 Mean Residual Moisture 
Pure IVS 4.16 3.99 2.73 3.63% ± 0.78% 
Sucrose 2.30 2.98 2.32 2.53% ± 0.39% 
Trehalose 2.51 3.33 3.18 3.01% ± 0.44% 
Lactose 2.34 2.86 3.28 2.83% ± 0.47% 
Sorbitol NC* NC* NC* NC* 
Mannitol 1.93 2.78 2.72 2.48% ± 0.47% 
Proline NC* NC* NC* NC* 
Serine NC* NC* NC* NC* 
Glutamic Acid NC* NC* NC* NC* 
Dextran 40 3.15 2.95 2.74 2.95% ± 0.21% 
PEG 3350 NC* NC* NC* NC* 
Gelatin 3.42 3.10 2.85 3.12% ± 0.29% 
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the cakes were melt back and difficult to collect. Therefore residual moistures of 
these excipients could not be calculated. 
 The Brazilian regulatory agency (MAPA) recommends that residual moisture 
do not pass 3% (Brasil, 1988). The IVS without excipient addition and gelatin did 
not pass the test. The trehalose was slightly above the recommended but since the 
test is influenced by many factors (temperature, operating time, air humidity), it can 
be said that trehalose passed the test and furthermore the lyophilized trehalose 
cake will be reevaluated. The other excipients analyzed had residual moisture 
under the regulatory claims. 
 
4.4.3 Best excipients selection 
  
 The IVS without any excipient formed a cake that passed in the visual 
aspects tests and almost passed the residual moisture test. This was possible 
because the IVS is 10 times concentrated. Even with the 5 times buffer exchange, 
there could still be traces of sugar, fetal bovine serum, amino acids and other 
metabolites that probably stabilized the IVS during the lyophilization. Lang and 
Winter (2009) demonstrated that sodium chloride interfere in lyophilization in 
concentrations superior to 60 mmol/L by aggregating molecules. The sodium 
chloride concentration on NT buffer is 50 mmol/L, so the presence of this salt only 
improves the tonicity of the vaccine. 
 The amino acids cakes melt back. It occurred probably due theirs 
ineffectiveness in protecting the IVS when used as only excipient, despite the 
excipients already present in the pure IVS. It use can have better results when 
associated with excipients of a different kind.  
 The book Laboratory Techniques in Rabies describes two protocols utilizing 
gelatin as excipient. In this work gelatin provided good cakes but after 
reconstitution it did not homogenized within the desired time which discarded the 
use of this excipient in future in vivo tests. 
 Trehalose was described as a good cryo and lyoprotector by Gupta and 
collaborators (1996) and Sarkar and collaborators (2003) for respiratory syncytial 
virus vaccine and pest des petites ruminants vaccine respectively. Caricati (2010) 
also tested different excipients for rabies vaccine lyophilization, obtaining 
interesting results for trehalose, sucrose and PEG 3350. The present work also 
presented good results for trehalose and sucrose in terms of visual aspects and 
residual moisture. However PEG 3350 which is very used as stabilizing agent in 
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lyophilization had poor results which were a disappointing result. PEG performance 
can also be improved if coupled with other excipients. 
 Lang and Winter (2009) also tested mannitol as excipient. When used alone 
mannitol presented good results for appearance and residual moisture. When 
coupled with trehalose, the resultant cake had a very robust crystalline matrix 
leading to a more elegant final product and enabling shorter drying times. Based on 
these results, in next lyophilization experiments mannitol and trehalose could be 
coupled together to test the resultant cake.  
Sucrose, at concentrations 1 to 68% has quite frequently been used for the 
cryopreservation of microorganisms (Hubálek, 2003). Law and Hull (1968) tested 
the stabilizing effect of sucrose for the respiratory syncytial virus and its infectivity, 
obtaining good results. Sehgal and Das (1975) studied the effect of freezing upon 
the bean mosaic virus using sucrose as stabilizer and also obtained good results. 
 Dextran, as well as sorbitol and mannitol are inert excipients. They provide 
elegance to lyophilized cakes because easily crystallize under low temperatures 
and are used in biopharmaceutical vaccines that use lower doses per vial and 
consequently have lower mass. In these cases, the inert excipients provide more 
volume and can be coupled with amorphous excipients generating a two phase 
solid: one amorphous with the active principle and one crystalline with the inert 
excipient (Caricati, 2010). The use of dextran and mannitol in the present work 
provided cakes with good appearance but it is necessary to know if the antigen was 
protected during the lyophilization experiment. However sorbitol cakes collapsed 
and further investigation will occur to understand the problems involved. 
In summary, the best excipients tested were sucrose, trehalose, lactose, 
mannitol and dextran 40. Formulations with these excipients can be tested in vivo 
to evaluate if the viral proteins still active and the vaccine have potency. Also a 
formulation with the clarified IVS five times concentrated without excipients addition 
should be tested in vivo to verify if the residual metabolites alongside the buffer 
exchange are sufficient to maintain the rabies vaccine potency. Based on that, five 
excipients were selected for posterior in vivo test: pure IVS, sucrose, trehalose, 
mannitol and dextran 40. Also, the cost of excipients must be taken into account to 
determine the best excipients. Within the five best excipients, sucrose is the 
cheapest and dextran 40 is the most expensive, so it is necessary that the best 
excipient also doesn’t increase the final price of the product enabling the 






At the final of the development experiment the growth curves for four BHK-
21 cells cultivated in 1.5 L spinners under different viral inocula were determined. 
Parameters like kinects, viability, infection rate, and virus titration were calculated 
and discussed in order to comprehend the cell growth before and after the 
infection. The maximum specific growth rate of the four spinners was in accordance 
with those obtained in optimized animal cell cultures. The metabolic analysis 
showed that in none of the days glucose was absent and lactate production did not 
achieve a limiting concentration. The infection rate established the third day post 
infection as beginning of infected culture harvests. The virus titration showed that 
positive control had the best graphic area above the cut off, determining that 
positive control (1% of spinner volume) was the best viral inoculum. 
The best lyophilization protocol was determined and several excipients were 
tested with this protocol. The IVS without any excipient alongside trehalose, 
sucrose, lactose, mannitol and dextran 40 presented lyophilized cakes with the best 
appearance. Serine, glutamic acid, proline, PEG 3350 and sorbitol cakes collapsed 
during lyophilization. In the reconstitution tests only gelatin was reproved and in the 
pH tests only glutamic acid was reproved. Sucrose, mannitol, trehalose, lactose 
and dextran 40 passed the residual moisture test. The lyophilization experiments 
selected five excipients for posterior in vivo tests: pure IVS, sucrose, trehalose, 
mannitol and dextran 40. 
6. Perspectives 
 
Based on the results obtained in this experiment, future work can be done: 
the development experiment will be repeated with the same conditions to compare 
the results; a pool of positive control harvests will be made and inactivated with 
beta-propiolactone; this inactivated viral suspension will be concentrated ten times 
and the medium will be exchanged with NT buffer for lyophilization experiments; 
the IVS will be formulated and freeze dried using the same work protocol; the 
lyophilized vials will be tested for all in vitro and in vivo tests demanded by the 
Brazilian regulatory agency (MAPA) with the excipients selected and combinations 
of these excipients. Also an economical study will be made for the best in vivo 







































Figure 1.3: Cycle of viral infection and replication of RABV inside one neuron. 















Figure 3.3: Direct immunofluorescence assay ready for reading. Each blue square 
represents one sample. The markings are drawn on the opposite side of the lamina 








Table 3.2: Scheme of samples and dilutions for virus titration in 96 wells microplate. 
The sample “0” was applied without dilution. CC means Cell Control where no virus 
was added. Examples: “Std -2” signifies the standard diluted 100 times (10
-2
); “4dpi 




















Figure 3.4: Example of one microplate filled with samples. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Std -2 Std -2 1dpi 0 2dpi 0 3dpi 0 4dpi 0 5dpi 0 6dpi 0 7dpi 0 8dpi 0 9dpi 0 10dpi 0 
B Std -3 Std -3 1dpi -1 2dpi -1 3dpi -1 4dpi -1 5dpi -1 6dpi -1 7dpi -1 8dpi -1 9dpi -1 10dpi -1 
C Std -4 Std -4 1dpi -2 2dpi -2 3dpi -2 4dpi -2 5dpi -2 6dpi -2 7dpi -2 8dpi -2 9dpi -2 10dpi -2 
D Std -5 Std -5 1dpi -3 2dpi -3 3dpi -3 4dpi -3 5dpi -3 6dpi -3 7dpi -3 8dpi -3 9dpi -3 10dpi -3 
E   1dpi -4 2dpi -4 3dpi -4 4dpi -4 5dpi -4 6dpi -4 7dpi -4 8dpi -4 9dpi -4 10dpi -4 
F   1dpi -5 2dpi -5 3dpi -5 4dpi -5 5dpi -5 6dpi -5 7dpi -5 8dpi -5 9dpi -5 10dpi -5 
G CC  1dpi -6 2dpi -6 3dpi -6 4dpi -6 5dpi -6 6dpi -6 7dpi -6 8dpi -6 9dpi -6 10dpi -6 







































Reagent (molarity) Mass used 
NaCl (0.13 mol/L) 7.600g 
Tris-HCl (0.05 mol/L) 6.057g 
pH adjusted to 7.6 























Figure 4.2 Examples of classes in a direct immunofluorescence assay. The cells 
are stained in red and the virus in green. The magnificence of the images is 50 
times although during the test the evaluation is done using 100 times. A – Class 1: 
from rare focus to 25% of fluorescent focuses (Pos. Control at 1 dpi); B – Class 2: 
from 25% to 50% of fluorescent focuses (MOI 0.01 at 2 dpi); C – Class 3: from 50% 
to 75% of fluorescent focuses (Pos. Control at 2 dpi); D – Class 4: more than 75% 



































Figure 4.4 Examples of positive and negative fields in the rabies virus titration. The 
cells are stained in red and the virus in green. The magnificence of the images is 100 
times. A – Positive field with a great amount of virus (MOI 0.03 at 3 dpi with 10
-1
 
dilution); B – Positive field with more diluted virus (MOI 0.03 at 3 dpi with 10
-2
 
dilution); C – 2 fluorescent focus yet positive field (MOI 0.03 at 3 dpi with 10
-5
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